By Sabela Ojea
Iovance Biotherapeutics on Friday said its biologics license application for lifileucel to treat advanced skin cancer was approved by the Food and Drug Administration. Shares of the biotechnology company climbed 16% to $8.72 in after-hours trading.
Lexicon Pharmaceuticals said its heart-failure treatment Inpefa received Food and Administration approval. Shares of the biopharmaceutical company rose 15% to $3.65 in after-hours trading.
The U.S. stock markets will be closed Monday for the Memorial Day holiday.
Write to Sabela Ojea at [email protected]; @sabelaojeaguix
Read the full article here
